Introduction
============

Antipsychotic-induced weight gain (AIWG) is a common and limiting side effect of antipsychotic treatment, especially of the widely prescribed second-generation antipsychotics (SGA).^[@bib1]^ Intersubject variability in this adverse effect may be explained in part by individual genetic differences; heritability may be as high as 80% based on comparisons of clozapine-treated monozygotic twins and sex-matched siblings.^[@bib2]^ Although AIWG is thought to be multifactorial, most of the extant research has focused on monoaminergic systems given their role in direct drug effects and their involvement in appetite, satiety, metabolism and activity.^[@bib3],\ [@bib4],\ [@bib5]^ Relatively modest variance in AIWG has been explained by association of common variants in these systems, suggesting that additional moderators in other pathways are likely, rare variants may be involved, or that confounding environmental effects exist. Further support for the existence of novel candidates is provided by pharmacogenomic analyses of the CATIE study of SGA-treated adults with schizophrenia, in which weight gain and metabolic effects were variably associated with several genes not considered to be 'drug targets\'.^[@bib6]^

Energy balance pathways
-----------------------

Energy intake and expenditure are regulated by the central nervous system, liver, gastrointestinal tract and adipose tissue to maintain energy balance. In the central nervous system, melanocortin 4 receptor (MC4R) signaling has a key role in regulating feeding behavior in the hypothalamus. The central melanocortin system regulates hepatic and adipocyte lipid metabolism.^[@bib7],\ [@bib8]^ Mutations in the *MC4R* gene are the most common monogenic cause of severe obesity in humans.^[@bib9]^ In addition, the mesolimbic dopamine pathway modulates reinforcing and motivational effects of food. The *FTO* (fat mass and obesity-associated) gene, highly expressed in the hypothalamus,^[@bib10]^ was identified by a genome-wide association study for its strong association with body mass index (BMI)^[@bib11]^ and this link was subsequently replicated independently and in a meta-analysis.^[@bib12]^ FTO expression appears to be sensitive to fasting and feeding.^[@bib13],\ [@bib14]^

Leptin (LEP) promotes satiety and leanness through multiple inputs to the energy balance circuit. LEP is secreted by adipose tissue in proportion to fat stores, and activates hypothalamic MC4R signaling to inhibit feeding and increase energy expenditure.^[@bib15]^ Recently, effects on reinforcement and motivation via mesolimbic dopamine signaling have been demonstrated.^[@bib16],\ [@bib17]^ Peripherally, LEP regulates lipid and glucose metabolism through the autonomic nervous system.^[@bib18],\ [@bib19]^ Obesity-producing spontaneous null mutations in *LEP* and the LEP receptor (*LEPR*) in mice prompted its discovery.^[@bib20]^ LEP antagonism in rats increases feeding, promotes weight gain and reduces activity.^[@bib21]^ Although humans genetically lacking LEP are morbidly obese,^[@bib22]^ mixed association results and a negative meta-analysis^[@bib23]^ suggest that *LEP* does not have a major role in common variability in body weight.

Endocannabinoids trigger feeding behavior and weight gain through stimulation of widely expressed cannabinoid 1 (CB1) receptors (CNR1).^[@bib24]^ In the brain, the endocannabinoid system regulates both mesolimbic reinforcement^[@bib25],\ [@bib26]^ and hypothalamic feeding pathways. CB1 signaling promotes feeding through positive effects on orexins^[@bib27]^ and inhibition of MC4R,^[@bib28]^ and is in turn stimulated by ghrelin^[@bib29]^ and inhibited by LEP^[@bib30]^ and cholecystokinin.^[@bib31]^ Endocannabinoid signaling in the liver and adipose tissue regulates lipid metabolism, adipogenesis and adiponectin release.^[@bib32]^ CB1 receptor agonism increases and antagonism reduces food intake and body weight in both humans and animal models.^[@bib33],\ [@bib34]^ Mice lacking CB1 expression exhibit hypophagia and leanness at baseline, and are resistant to high-fat diet-induced metabolic changes, behaviors and obesity.^[@bib35]^ Polymorphisms in CNR1 and the gene encoding the catabolic enzyme (fatty acid amide hydrolase (*FAAH*)) have been associated with obesity phenotypes; however, data are mixed.^[@bib36],\ [@bib37]^ In the RIO-North America trial, 2-year treatment with a CB1 antagonist, rimonabant, in combination with a healthy diet, resulted in modest reductions in weight, waist circumference and cardiometabolic risk factors.^[@bib38]^ The drug did not reach the US market, however, due to psychiatric side effect concerns.

*Energy balance candidate genes in AIWG*
----------------------------------------

A few reports have begun to investigate whether variants in metabolic and appetite gene loci, such as *LEP*, may moderate AIWG.^[@bib5]^ These studies were prompted by observed increases in plasma LEP levels during SGA treatment.^[@bib39]^ Common *LEP* gene variants have reportedly moderated AIWG in some but not all studies,^[@bib5]^ including one pediatric sample.^[@bib40]^ Variants mapping adjacent to the *MC4R* gene have recently been demonstrated to predict AIWG in multiple independent samples.^[@bib41],\ [@bib42]^ Given the role of the endocannabinoid system in energy balance and observed CNR1 upregulation in response to antipsychotic treatment,^[@bib43]^ two recent pharmacogenomic studies have supported a contribution of endocannabinoid involvement. One report demonstrated moderation of AIWG in schizophrenia by a functional polymorphism in *CNR1*.^[@bib44]^ A second study demonstrated an association between AIWG and a nonsynonymous variant in the gene encoding the degradative enzyme, *FAAH*.^[@bib45]^

The established role of the melanocortin, LEP and endocannabinoid systems in energy balance and the association of gene variants with human obesity strongly suggest these systems as possible moderators of AIWG, perhaps as an alternative pathway to direct drug action at monoaminergic and other targets. Relatively few studies have examined the effects of common gene variants in these systems, and to our knowledge, none have attempted a systematic, combined examination of these loci in relation to AIWG. In addition, most reports have not queried each locus thoroughly, relying instead on rather few frequently studied polymorphisms. Importantly, extant genetic studies of variants in the energy balance system have been mainly limited to adults, despite common use of SGAs in children. Reports suggest that pediatric populations are at equal or greater risk of AIWG.^[@bib46],\ [@bib47],\ [@bib48],\ [@bib49]^ In the NIMH Research Units on Pediatric Psychopharmacology (RUPP) trials, weight gain above that predicted with normal development was evident after just 8 weeks and continued after 6 months of risperidone exposure.^[@bib50]^ Other longitudinal studies show persistent effects at 1 year.^[@bib48]^ Studying AIWG in children has several scientific advantages, such as fewer concomitant and potentially confounding medical comorbidities and medications, and lower rates of institutionalization, smoking and substance use/abuse. Further, increased weight in children confers serious health risks, social impairment, challenges to self-esteem and risk for adult obesity. In light of the potential importance of energy balance genes as moderators of AIWG and sparse investigation in pediatric samples, we examined the association of genetic variants in these systems with weight gain in our combined sample from two clinical trials of children and adolescents receiving risperidone treatment for severe irritability associated with autism spectrum disorders (ASDs).^[@bib51],\ [@bib52]^

Materials and methods
=====================

The research was conducted by the RUPP Autism Network under two protocols approved by individual site Institutional Review Boards and by a National Institute of Mental Health Data Safety Monitoring Board. Written informed consent (and assent from the child, when capable) was obtained from a parent or guardian before enrollment. Youth (ages 4--17 years) meeting DSM-IV criteria for ASD (autism, Asperger\'s disorder, pervasive developmental disorder not otherwise specified) accompanied by severe irritability (aggression, tantrums, and/or self-injurious behaviors) defined by a score of ⩾18 on the Aberrant Behavior Checklist Irritability subscale were treated for 8 weeks with risperidone or placebo as part of two controlled trials, RUPP^[@bib51]^ and RUPP-PI (RUPP-Psychosocial Intervention).^[@bib51],\ [@bib52]^ Only 10% of subjects had previously received (ineffective) antipsychotic treatment; subjects with prior adequate trials of risperidone were excluded. In the RUPP sample, subjects included both those randomized first to risperidone in the 8-week acute phase and non-responders to 8 weeks of initial placebo treatment who were then openly treated with risperidone according to an identical titration and assessment protocol.^[@bib51]^ In the RUPP-PI study, all subjects received risperidone, titrated as in the RUPP study, with or without parent behavior management for up to 24 weeks.^[@bib52]^ Of the 225 total outpatients enrolled from the two trials, weekly measures of weight, height, BMI and genotype data were available for a combined 184 subjects from their initial 8-week acute exposure to risperidone. Plasma drug and metabolite levels were analyzed for the RUPP sample according to previously published protocols.^[@bib53]^

The RUPP and RUPP-PI groups were compared using the appropriate *χ*^2^, analysis of variance or *t*-test to ensure comparable samples ([Table 1](#tbl1){ref-type="table"}). Baseline variables that were significantly different between the two groups were tested in the final model and dropped if they showed no significant effect on outcome. Weight was transformed to standardized *z*-scores using anthropometric indices based on the 2000 CDC growth charts using the CDC SAS program,^[@bib54]^ as described in a previous report.^[@bib50]^ A separate repeated measures mixed effects model was constructed for each single-nucleotide polymorphism (SNP) with change in weight *z*-score from baseline as the main outcome. Genotype, visit (as a continuous variable) and interaction of genotype by visit were entered as predictors, controlling for baseline weight *z*-score. Other potentially confounding covariates were entered in the initial model such as dose, plasma drug level and ethnicity, but were nonsignificant and therefore dropped from the final model.

The linkage disequilibrium (LD) structure of *MC4R*, *LEP* and *CNR1* were examined using the Broad Institute Tagger software^[@bib55]^ to select markers ([Table 2](#tbl2){ref-type="table"}), which span each gene and capture common variability (\>1%) in this genomic region, with a mean max *r*^2^\>0.98 for *LEP* and *r*^2^=1 for *MC4R*. Our *CNR1* tag is less robust according to the latest genome build, with a mean max *r*^2^\>0.61 for alleles with \>10% frequency across the CNR1-coding region. Tags were chosen based on the European Caucasian reference genome, given that our population is 70% Caucasian and thus provides little power to detect population-specific alleles in non-Caucasian subsets. A well-characterized, functional variant (rs324420) in *FAAH* was included to more comprehensively evaluate the endocannabinoid system. Six SNPs in *FTO* with genome-wide association study support for obesity were also examined; however, four of these were in near perfect LD, thus only one was included in the final analyses. Genomic DNA was extracted from whole blood using QiaAmp DNA Blood Mini Kits (Qiagen, Valencia, CA, USA). Genotyping was performed using the TaqMan genotyping platform (Life Technologies, Grand Island, NY, USA) with Qiagen Type-it Fast SNP Probe PCR Kit (Qiagen) according to manufacturer\'s protocols. All markers were in Hardy--Weinberg equilibrium, 10% of the data set was genotyped in duplicate with perfect concordance, and allele frequencies were consistent with those reported by the HapMap Consortium ([Table 2](#tbl2){ref-type="table"}).^[@bib56]^ Functional potential of associated SNPs was explored using online databases, including the online UCSC Genome Browser^[@bib57]^ with ENCODE tracks^[@bib58]^ and the Broad Institute\'s HaploReg online resource (accessed 4 November 2012).^[@bib59]^

A combined risk variable was constructed using the three significant markers, in part to examine the relative independence of each marker. Genotype at each locus was given a score of 0 or 1, with 1 denoting the presence of at least one risk allele. Scores were summed across the three loci and each subject received an overall risk score ranging from 0 to 3. A similar repeated measures mixed effects model (predicting change in weight *z*-score based on risk score, visit and visit by risk score) was applied, with baseline weight as a covariate.

Results
=======

The two studies were roughly equivalent with respect to demographic and baseline characteristics, final risperidone daily dose and weight gained ([Table 1](#tbl1){ref-type="table"}). Statistical comparisons of the two study populations showed small clinical differences: RUPP-1 subjects were 16.7 months older, weighed 0.27 kg more at baseline and received an average of 0.25 mg less total daily risperidone compared with RUPP-PI participants. Whereas both samples were predominantly Caucasian (∼70%), there were minor ethnicity differences across the samples. As a result, significant associations with gene variants were repeated with ethnicity and risperidone dose as covariates. The mean absolute weight increase for the combined sample ([Table 1](#tbl1){ref-type="table"}) was 2.68±1.74 kg (9.8% of baseline) with an increase in BMI of 8.3% from baseline (final BMI=19.3±3.9) following 8 weeks of risperidone exposure (mean final dose 2±0.62 mg per day). Of note, the decrease in Aberrant Behavior Checklist-Irritability subscale score (primary outcome) from baseline to 8 weeks was significantly inversely correlated with weight gain in kilograms (*r*=−0.36, *P*\<0.0001). Drop-out rates were very low with more than 95% completing the entire 8-week study.

Three independent gene variants were associated with z-score weight change at a Bonferroni-corrected significance level, one in *LEP* and two in *CNR1* ([Figure 1](#fig1){ref-type="fig"}; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The T-allele of the *CNR1* rs806378 polymorphism predicted an allele dosage-dependent increase in AIWG (*P*=1.0 × 10^−6^, [Figure 1a](#fig1){ref-type="fig"}). The increase in age-corrected BMI for the three genotype groups was 1.85 for TT homozygotes, 1.57 for CT heterozygotes and 1.34 for CC homozygotes. The G-allele of the commonly studied (rs1049353) synonymous variant in the large, final exon of *CNR1* conferred an independent risk for weight gain (*P*=9.6 × 10^−5^), suggesting allelic heterogeneity at this locus. G-allele carriers gained more weight than AA homozygotes, with change in BMI of 1.25 for GG homozygotes, versus 1.49 for AG heterozygotes and AA homozygotes. The G-allele of the *LEP* rs7799039 promoter SNP acted dominantly to increase weight gain compared with A-allele homozygotes (*P*=1.4 × 10^−4^, [Figure 1b](#fig1){ref-type="fig"}). Change in BMI of GG homozygotes and AG heterozygotes was 1.37 and 1.43 respectively, compared with 1.07 in AA homozygotes. A second marker, rs10244329, produced a weaker association (9.6 × 10^−3^) that was a result of modest LD with this associated variant but conferred no independent effects. None of the *FTO* obesity-associated markers were related to AIWG in our sample ([Table 2](#tbl2){ref-type="table"}). Several *MC4R* variants showed a trend association, but none met significance after correction for multiple comparisons (adjusted significance threshold for 19 markers *P*\<0.003). The single nonsynonymous variant in *FAAH* did not achieve significance in our data set.

Although weight gain was not correlated with risperidone dose (*r*=−0.09, *P*=0.24), we repeated the analyses using dose as a covariate to rule out any confounding effects; risperidone dose did not contribute to the effects of genotype (rs806378, *P*=0.68; rs1049353, *P*=0.68; rs7799039, *P*=0.86). In addition, as trough plasma levels were obtained for the RUPP samples, the markers with significant associations were analyzed in the RUPP subsample using plasma level as a covariate. Surprisingly, despite the much smaller sample size (*n*=34), rs1049353 (*P*\<0.005) and rs7799039 (*P*\<0.05) both retained nominal significance, however, rs806378 did not (*P*=0.26); plasma level did not account for these effects (rs806378, *P*=0.41; rs1049353, *P*=0.49; rs7799039, *P*=0.54). Finally, although there were no significant difference in weight gained (Z-score) in the Caucasian versus non-Caucasian groups, analyses of the three significant markers included ethnicity as a covariate and were reanalyzed in the Caucasian subsample (*n*=119). No main effect of ethnicity was observed (rs806378 *P*=0.60, rs1049353 *P*=0.66, rs7799039 *P*=0.86), *P*-values were similar whether or not ethnicity was included in the model, and all three SNPs retained significance in the smaller Caucasian subsample (rs806378, *P*=1.8 × 10^−3^; rs1049353, *P*=8.63 × 10^−6^; rs7799039, *P*=4.5 × 10^−5^).

In order to test for overlapping or interactive effects between these three variants, we calculated a risk score for each subject by assigning one point for the presence of a risk allele at each identified locus ([Figure 2](#fig2){ref-type="fig"}). This model strongly predicted weight gain in both the overall sample (*P*=1.29 × 10^−9^) and the Caucasian subset (*P*=2.13 × 10^−11^). The addition of each risk allele conferred an independent risk; subjects with 0 or 1 risk alleles (combined as only one subject had no risk alleles) gained the least weight and those with three alleles gained the most (Cohen\'s D effect size 0.46 for 0/1 versus 2 and 0.85 for 0/1 versus 3). In all, 64% of the variance in weight gained was explained by the combined risk by time model.

Discussion
==========

Our results form strong support for individual genetic variation in the *LEP* and *CNR1* genes as moderators of AIWG. SGAs may impact appetite, weight gain and energy expenditure through direct or indirect interactions with these key regulators of energy balance. Although the exact mechanisms of these effects are unknown, our data suggest that genetic regulation of energy balance components may impact energy homeostasis in the face of antipsychotic exposure. The prominent role of promoter, rather than coding, variants in both genes implies that regulation of gene expression may be an important mechanism. Future studies should examine gene expression profiles during SGA exposure, with particular interest in the expression of the significantly associated loci identified in this report.

In this sample of children and adolescents with ASD, individuals with at least one copy of the T-allele of *CNR1* SNP rs806378 showed greater weight gain during low-dose risperidone exposure, evident even after only the first 8 weeks of treatment. As our data are in agreement with a prior study in adults with schizophrenia receiving olanzapine,^[@bib44]^ this variant may confer broad risk for AIWG. This SNP localizes immediately adjacent to the coding region in either the putative promoter, the 5′ untranslated region or the large first intron in alternative transcripts of *CNR1*, and mechanistically it has been suggested to impact a binding site for a transcription factor involved in regulating hypothalamic feeding drives.^[@bib44]^ Despite the inclusion of the upstream alternative promoter and untranslated exon in several prior studies, all association signals have localized to the 3′ LD block tagged in the present analyses. Allelic heterogeneity and possible differential ethnic risk affecting this locus may help to explain disparate findings in published studies. Another nearby SNP (rs806377) and a 3′ untranslated region polymorphism (rs806368) previously reported to associate with obesity phenotypes were not associated with AIWG in our sample.^[@bib37],\ [@bib60]^ Association with fat mass and BMI of the G-allele of synonymous SNP rs1049353 was previously reported and replicated,^[@bib61],\ [@bib62]^ although not all studies are in agreement.^[@bib60],\ [@bib63],\ [@bib64]^ In all positive reports, including the present study, the G-allele is associated with risk for weight gain or related phenotypes. Synonymous SNPs may be directly relevant by altering translational efficiency or by impacting mRNA processing, stability or localization, or may reflect indirect association through LD with a nearby functional variant. Indeed, HaploReg analysis indicates that this SNP is in near perfect LD with a 3′ untranslated region variant mapping to a region of active transcription factor binding (rs4707436). The two associated *CNR1* variants reflect independent associations, as LD between these two SNPs is negligible (*r*^2^=0.01). Despite previous support,^[@bib45]^ the single nonsynonymous variant in *FAAH* was non-significant in our data set.

We report a substantial contribution of the *LEP* rs7799039 (G-2548A) promoter SNP with individual differences in weight gain, as have multiple prior studies, including one in children.^[@bib40]^ In our sample, the G-allele conferred a dominant effect on risk for weight gain. Data from several groups support this directionality of effect for AIWG^[@bib65],\ [@bib66],\ [@bib67],\ [@bib68],\ [@bib69]^ and related phenotypes.^[@bib70],\ [@bib71]^ A few studies have found no evidence for association at this locus.^[@bib72],\ [@bib73]^ Three studies have found association of the A-allele with AIWG in Asian populations,^[@bib74],\ [@bib75],\ [@bib76]^ as well as a single smaller mixed-ethnicity pediatric study, which also showed LEP elevation for carriers of the A-allele.^[@bib40]^ Taken together, our data stand in agreement with the majority of reports; those studies with contrary patterns of association with AIWG and the A-allele appear to differ by virtue of effects of ethnicity. Of the two negative reports, one sample was significantly smaller than ours, and both involved a mixture of various antipsychotics, including other concomitant medications. It is conceivable that some associations with AIWG will emerge to be medication specific. Interestingly, in the only prior pediatric report, A-carriers had greater weight gain and higher LEP concentrations at lower BMIs overall, however, the magnitude of the increase in LEP with BMI was greater for GG homozygotes, arguing that this SNP may indeed produce differential LEP expression.^[@bib40]^ In concordance with this finding, higher transcription factor binding to the *LEP* promoter, LEP expression and LEP secretion has been demonstrated in non-obese AA homozygotes compared with G-carriers.^[@bib77]^ Interestingly, *in silico* investigation also suggests that this SNP may be functional, as it tags an LD block annotated by HaploReg as containing multiple enhancer elements.

The marginal association of SNPs in the obesity-related gene, *MC4R* deserves mention. Our *MC4R* results stand in contrast to recent strong associations with AIWG. However, we note three possibly relevant study differences. Our sample tested only associations with risperidone monotherapy, whereas the positive *MC4R* reports examined associations with multiple, mostly other SGAs, not risperidone. Our sample is considerably younger (mean age 9 years) than most; it is conceivable that age and developmental stage interacts with gene--weight gain relations. Our sample is also unique in that is only includes subjects with ASD, rather than the majority of reports of adolescents and adults with psychotic and other disorders. Each of these differences may be relevant to genetic associations with AIWG. Clinically, it is of note that the inverse correlation of AIWG with clinical improvement on the primary outcome measure concurs with our RUPP report that weight gained negatively mediated risperidone benefit,^[@bib78]^ which could have implications for drug development. However, the mechanism of antipsychotic action in autism-associated aggression may be distinct from activity in psychotic disorders; indeed, the relationship between efficacy and weight gain appears to be positively correlated in studies of psychosis.^[@bib79],\ [@bib80]^

Our investigation likely benefited from several features: the largely treatment-naive sample of youth with a single disorder (ASD), observations of weight with risperidone monotherapy only, weekly monitoring and data collection allowing a powerful repeated measures statistical model and a more rigorous query of candidate genes. As repeated measures of weight gain across eight visits were tightly correlated (*r*=0.95), this study was powered to detect effect sizes ranging from 0.15 to 0.32 based on the minor allele frequency of the variant. The clinical impact of the variants reported here appear significant given the large effect size. It is conceivable that these associations could become even more robust if measured over longer periods of drug exposure. To our knowledge, this study represents the only examination of the endocannabinoid system in children, who may suffer greater morbidity both in terms of magnitude of weight gained and health impact across the lifespan. Importantly, the support for involvement of CNR1 signaling suggests that the use of known drug modulators of this system, such as those similar to rimonabant, could limit the extent of AIWG, especially in those individuals at higher genetic risk.

Although our study is limited by a relatively modest number of subjects, results did withstand correction for multiple testing. Although a functional variant in the FAAH enzyme and highly associated *FTO* markers were chosen for inclusion based on prior data, these genes were not comprehensively screened. A larger sample would provide the statistical power to permit the inclusion of additional markers, either within these genes or other components of the energy balance system, or allow a full selection-unbiased genome-wide association study. Similarly, other metabolic response 'phenotypes\', such as hip and waist circumference, lipid profile and measures of glucose metabolism, could also be examined,^[@bib6]^ although the current sample size lacks desired power for broader exploration.

Taken together, our data and prior evidence support a moderating role of genetic variation in the LEP and endocannabinoid system on AIWG. Additional efforts to replicate and extend these findings to larger samples, to understand the biological basis for these associations and to examine possible clinical implications by *a priori* risk prediction and genotype-driven treatment matching are suggested as future directions. Polygenic inheritance, small effect sizes and genetic and phenotypic heterogeneity have limited the identification of genetic moderators of complex phenotypes. However, understanding the risk for tractable and quantitative adverse drug effects informed by underlying biology may pose a less complex genetic question. The pharmacogenetics of AIWG may offer a window into the intricate physiology of energy balance and guide the personalization of treatment to improve clinical outcomes.
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###### 

Click here for additional data file.

![Gene variants predict weight gain across 8 weeks of risperidone treatment. (**a**) A greater risk for weight gain is conferred by T-allele dosage at cannabinoid receptor (*CNR1*) rs806378 (*P*=1.0 × 10^−6^). (**b**) The G-allele of leptin (*LEP*) rs7799039 acts dominantly to increase risk for antipsychotic-induced weight gain (*P*=1.4 × 10^−4^), whereas AA homozygotes are relatively protected.](tp201326f1){#fig1}

![Amount of weight gain is moderated by risk allele load. A risk score (0--3) was assigned to each subject corresponding to the number of loci with risk alleles present for each significant marker (leptin rs7799039 and cannabinoid receptor 1 rs806378 and rs1049353). Risk allele dosage predicted amount of weight gain (*P*=1.29 × 10^−9^, Cohen\'s D effect size=0.85). Only one subject had no risk alleles and was therefore included in the 1-allele group.](tp201326f2){#fig2}

###### Characteristics of the RUPP, RUPP-PI and combined RUPP risperidone Autism samples

                               *RUPP (*n*=71)*   *RUPP-PI (*n*=110)*   *Combined (*n*=181)*   P*-value*
  ---------------------------- ----------------- --------------------- ---------------------- -------------------------
  Gender (*n* (%) male)        56 (78.9%)        92 (83.6%)            148 (81.8%)            *χ*^2^=0.66, *P*=0.4177
  Baseline age (months)        106.66±34.5       89.96±29.0            96.5±32.3              *T*=3.51, *P*=0.0006
  Baseline BMI                 18.2±4.9          17.7±3.1              17.9±3.92              *T*=0.85, *P*=0.40
                                                                                               
  *Ethnicity* (*n* (%))                                                                       *χ*^2^=14.9, *P*=0.02
   White, non-Hispanic         51 (71.8%)        74 (67.3%)            125 (69.0%)             
   Black, non-Hispanic         6 (8.5%)          20 (18.2%)            26 (14.4%)              
   Native American             0                 2 (1.8%)              2 (1.1%)                
   Asian or Pacific Islander   7 (9.9%)          5 (5.5%)              13 (7.2%)               
   Hispanic                    2 (2.8%)          7 (6.4%)              9 (5.0%)                
   Black, Hispanic             0                 1 (0.9%)              1 (0.6%)                
   Other                       5 (7.0%)          0                     5 (2.8%)                
                                                                                               
  *Duration of treatment*                                                                      
   Median (range) weeks        8 (6--8)          8 (1--8)              8 (1--8)               *χ*^2^=4.08, *P*=0.54
  Final dose (mg)              1.84±0.63         2.09±0.59             2.00±0.62              *T*=−2.66, *P*=0.0084
  Mean weight gain (kg)        2.84±2.05         2.57±1.51             2.68±1.74              *T*=0.97, *P*=0.3317

Abbreviations: BMI, body mass index; RUPP, Research Units on Pediatric Psychopharmacology; RUPP-PI, RUPP-psychosocial intervention.

###### Association of genetic variants in energy balance pathways with AIWG

  *Gene*   *SNP ID (rs\#)*                         *Gene region*                         *Our MAF*   *HapMap MAF*   P*-value*              *Prior association*
  -------- --------------------------------------- ------------------------------------- ----------- -------------- ---------------------- ----------------------------------
  *FTO*    rs1421085                               Intron 1                              0.33        0.45           0.13                   ^[@bib12]^
           rs6499640                               Intron 1                              0.41        0.35           0.88                   ^[@bib81]^
           rs1121980                               Intron 1                              0.41        0.48           0.78                   ^[@bib12],\ [@bib82]^
           rs17817449[a](#t2-fn2){ref-type="fn"}   Intron 1                              0.39        0.45                                  ^[@bib83]^
           rs8050136[a](#t2-fn2){ref-type="fn"}    Intron 1                              0.38        0.45                                  ^[@bib12]^
           rs9939609[a](#t2-fn2){ref-type="fn"}    Intron 1                              0.38        0.45                                  ^[@bib11],\ [@bib73]^
  *MC4R*   rs8087522                               Promoter                              0.36        0.36           0.06                   ^[@bib41],\ [@bib84]^
           rs11872992                              Promoter                              0.12        0.13           0.03                   ^[@bib41],\ [@bib84]^
           rs8093815                               3′ Downstream                         0.32        0.33           0.07                    
           rs489693                                3′ Downstream                         0.39        0.34           0.03                   ^[@bib85]^
  *LEP*    rs7799039                               promoter                              0.43        0.49           **1.4 × 10**^**−4**^   ^[@bib72],\ [@bib86],\ [@bib87]^
           rs10244329                              Intron 1                              0.49        0.47           9.6 × 10^−3^           ^[@bib88]^
           rs12706832                              Intron 1                              0.49        0.57           0.09                    
           rs2071045                               Intron 2                              0.24        0.21           0.19                   ^[@bib89]^
  *CNR1*   rs806378                                Variable[b](#t2-fn3){ref-type="fn"}   0.24        0.26           **1.0 × 10**^**−6**^   ^[@bib44]^
           rs806377                                Promoter                              0.46        0.49           0.17                    
           rs1049353                               Synonymous                            0.23        0.23           **9.6 × 10**^**−5**^    
           rs806368                                3′UTR                                 0.18        0.25           0.26                    
  *FAAH*   rs324420                                Nonsynonymous                         0.25        0.21           0.19                   ^[@bib45]^

Abbreviations: AIWG, antipsychotic-induced weight gain; CNR, cannabinoid receptor; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; UTR, untranslated region.

*FTO* SNPs removed from analysis due to near perfect linkage disequilibrium with rs1121980.

rs806378 maps to either a promoter, 5′UTR, or intronic location in alternatively processed *CNR1* transcripts. Bolded *P*-values are significant after Bonferroni-correction for 19 tests.
